Rare Hemophilia Factors Market To Reach $490.4 Million By 2030

Rare Hemophilia Factors Market Growth & Trends

The global rare hemophilia factors market size is expected to reach USD 490.4 million by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several factor concentrates gaining marketing approvals from regulatory bodies, such as the U.S. FDA, are expected to provide a significant push to the market growth. In addition, the rising adoption of prophylaxis treatment by patients is expected to boost market growth in the coming years. Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life. The COVID-19 pandemic had a significant impact on the market growth.

The pandemic's emphasis on patient safety and infection control measures led to an increased awareness and importance placed on safety measures in the administration of specific clotting factor therapies. Healthcare providers and patients became more conscientious about following hygienic practices during treatment administration, such as proper disinfection, hand hygiene, and the use of personal protective equipment. This increased emphasis on patient safety measures may have long-term benefits for the administration of rare hemophilia factors. Despite the challenges posed by the pandemic, there was still a high demand for specific clotting factor therapies for rare hemophilia. Patients with rare hemophilia types still required these therapies to effectively manage and treat their condition.

Favorable government initiatives and mandates to increase diagnosis and treatment rates are boosting market growth. For instance, the U.S. Congress enacted the Orphan Drug Act (ODA) in 1983. From 1983 to 2015, around 3,647 drugs were designated the status of orphan drugs, and 554 drugs were approved by the U.S. FDA. The market players are constantly undertaking initiatives, such as innovative product launches and collaborations, to gain an advantage in the highly competitive market. For instance, in November 2022, the FDA announced its approval of an innovative gene therapy for the treatment of genetic blood-clotting Hemophilia B disorder. Kymriah, the gene-based therapy, is used for the treatment of B-cell precursor hemophilia patients below 25 years of age.

 Request a free sample copy or view report summary: Rare Hemophilia Factors Market Report

Rare Hemophilia Factors Market Report Highlights

• Factor VII deficiency dominated the market and accounted for a share of 35.1% in 2024. Factor XIII deficiency is expected to grow at the fastest CAGR of 7.1% over the forecast period.

• Recombinant therapies led the market and accounted for a share of 50.3% in 2024. Prophylactic treatments are expected to register the fastest CAGR of 7.5% over the forecast period.

• Hospital pharmacies held the largest market share of 59.9% in 2024. Online pharmacies are projected to grow at the fastest CAGR of 9.2% over the forecast period.

• North America rare hemophilia factors market dominated the global market with a revenue share of 38.7% in 2024. Asia Pacific rare hemophilia factors market is expected to register the fastest CAGR of 6.1% in the forecast period. 

Rare Hemophilia Factors Market Segmentation

Grand View Research has segmented the global rare hemophilia factors market report based on factor deficiency type, drug class, distribution channel, and region:

Rare Hemophilia Factors Deficiency Type Outlook (Revenue, USD Million, 2018 - 2030)

• Factor VII Deficiency

• Factor XI Deficiency (Hemophilia C)

• Factor XIII Deficiency

• Others

Rare Hemophilia Factors Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Recombinant Therapies

• Plasma-derived Therapies

• Prophylactic Treatments

• Others

Rare Hemophilia Factors Distribution Chanel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Rare Hemophilia Factors Regional Outlook (Volume, Kilotons; Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Rare Hemophilia Factors Market

• Takeda Pharmaceutical Company Limited

• Biogen

• Novo Nordisk A/S

• Bayer AG

• CSL

• Pfizer Inc.

• Sanofi

• F. Hoffmann-La Roche Ltd

• Swedish Orphan Biovitrum AB (publ)

• Octapharma AG

• Grifols, S.A.

• BioMarin